Jiangxi Bio has been honored as the “Annual Outstanding Value Leader in the Biopharmaceutical Industry,” with its scientific and technological innovation capabilities and platform value recognized.

9 month 16 Day, In “ 2026 International Finance and Economic Development Week - At the Hong Kong Financial Investment Forum and the China Science and Technology Innovation Value Ranking Awards Ceremony, Jiangxi Institute of Biological Products Co., Ltd. (hereinafter referred to as “Jiangxi Bio” or the “Group,” stock code: 6915.HK ) Awarded the “Annual Outstanding Value Biopharmaceutical Leading Enterprise” prize 。

This year’s selection is co‑hosted by the Hong Kong Commercial Daily and the Global Business Daily Alliance, with the Hong Kong Capital Markets Institute serving as the organizer. It ranks among the most prestigious and influential lists in the financial sector, themed “Anchor the Blueprint, Create Value,” and focuses on Chinese companies’ technological innovation and value discovery in the capital markets. Drawing on publicly available data from listed companies, as well as expert insights from financial institutions and industry specialists, the ranking evaluates outstanding enterprises across six key dimensions—innovation capability, strategic foresight, growth potential, and others—aiming to set industry benchmarks and foster synergistic development among technology, industry, and capital.

Jiangxi Bio Honored 2026 Year’s “Outstanding Value Biopharmaceutical Leader of the Year” 

Deeply cultivating a full‑chain industrial layout, showcasing the leading value of “biopharmaceuticals.” 

This award represents the capital market’s high recognition of Jiangxi Bio’s deep industry expertise and innovative achievements in the field of polyclonal antibodies (i.e., antiserums). As a globally leading, integrated, full‑chain biopharmaceutical platform company specializing in antiserums, according to… 2025 In terms of annual sales, the Group is the world’s largest producer of human tetanus antitoxin (for human use). TAT ) Supplier and exporter, continuously 19 It has maintained a leading position in the Chinese market for years, with its products exported worldwide. 30 Several countries and regions. 

Leveraging its rare, end-to-end industrial-chain integration capabilities, the Group seamlessly connects key links—including upstream horse‑resource assurance, iterative advancements in antigen development and antibody‑production technologies, and standardized manufacturing operations—and, supported by a robust global sales network, capitalizes on the synergistic advantages of its fully integrated value chain. This enables the rapid translation of research breakthroughs into large-scale production and commercialization, further solidifying the Group’s leading position in the field of equine‑derived polyclonal antibodies. 

Unleashing platform-level innovation potential and leading the development of horse-derived polyclonal antibodies. 

Based on the accelerating pace of innovation in the global biopharmaceutical industry, AI At a time of deep integration with biotechnology, the Group is upgrading and building a next-generation “ AEPC “Platform” (a digital and intelligent full‑industry‑chain platform for Ma Yuan’s polyclonal antibodies), with “ AI+ Fusion protein mRNA Antigen development platform and horse-derived F(ab’) ₂ The process platform serves as the technological backbone, centered on antigen development ( Antigen Development ), equine immunization ( Equine Immunization ), plasma processing and antibody purification ( Plasma Processing ) and commercialization ( Commercialization ) The four core components, integration will… AI Digital twins and intelligent manufacturing integrate R&D, production, sales, and governance, driving the research, development, and manufacturing of MaYuan’s polyclonal antibodies toward digital intelligence and standardization. 

As of 8 month 31 On that day, the group achieved 3 Commercialization of this product, and additionally 5 The candidate products have achieved phased breakthroughs in clinical research and commercialization. Leveraging… AEPC Platform-driven resource collaboration and the reuse of common technologies are enabling the Group to accelerate the advancement of “human pharmaceuticals.” + Through innovative translation of the “veterinary‑medicine” dual‑pipeline approach, we are accelerating the exploration and expansion of the application frontiers of polyclonal antibodies, with the aim of providing a practical model for technological upgrading and diversified development in the industry. 

Looking ahead, the Group will remain committed to its mission of “providing high-quality medicines to people worldwide,” anchoring itself in quality and leveraging innovation as its driving force, while continuously deepening its technological advancements in equine‑derived polyclonal antibody development and… AEPC Through platform development, we are accelerating the translation of our innovative pipeline into clinical applications and expanding our global footprint, ensuring that high‑quality scientific advances meet the needs of both human healthcare and animal health worldwide. 

Regarding Jiangxi Institute of Biological Products Co., Ltd. 

Jiangxi Institute of Biological Products Co., Ltd. (“the Group”) is a globally leading, platform‑based biopharmaceutical company that integrates the entire value chain of antiserum production. According to… 2025 In terms of annual sales, the Group is the world’s largest producer of human tetanus antitoxin (for human use). TAT ) Supplier and exporter, continuously 19 Yearly maintenance for Chinese users TAT Market-leading position, with products exported overseas. 30 In numerous countries and regions, the Group has cumulatively served over one billion patients worldwide. Upholding its mission to “provide high-quality medicines for people around the globe,” the Group leverages exceptionally stringent industry准入 standards, a rare end-to-end integrated industrial chain, and cutting-edge technological advantages to build a platform for human pharmaceuticals. + The “Veterinary Medicine” dual‑track pipeline is deeply focused on four key therapeutic areas—biotoxin poisoning, viral infections, bacterial infections, and immune modulation—while continuously expanding into blood‑derived product applications. 2026 Year, the Group upgraded and built “ AEPC “platform,” to AI Moreover, by integrating digital capabilities across the entire value chain—R&D, manufacturing, sales, and governance—the company is strengthening its proprietary technological barriers in the field of horse‑derived polyclonal antibodies, delivering safer and more effective solutions to address critical unmet needs in human medicine and animal health, and contributing China’s expertise to global public health. For more information, please visit: https://www.jxswzp.cn/ 。